A biopharma company developing a new drug for a rare form of cancer partnered with WEP Clinical to run an Expanded Access Program (EAP). Because the company’s drug is being developed to treat a rare condition, the clinical trial population is small. As such, the company wanted to be able to collect additional data from EAP patients to better understand patient’s quality of life and to gain additional insight on the drug safety profile. This data could be used to support clinical trial data when seeking product approval.


The company utilized WEP Clinical’s Real World Data collection platform to capture patient reported outcomes and additional clinical data from EAP participants. WEP Clinical’s platform allowed the company to review this data in real-time, which helped them to make important decisions regarding their clinical programs. It also demonstrated data validity, patient confidentiality, and regulatory compliance across international borders.